Microencapsulated chitosan nanoparticles for lung protein delivery.
暂无分享,去创建一个
[1] I. El-Gibaly. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. , 2002, International journal of pharmaceutics.
[2] R. Langer,et al. Drug delivery and targeting. , 1998, Nature.
[3] María J. Alonso,et al. Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration , 1999 .
[4] M. Duszyk. CFTR and lysozyme secretion in human airway epithelial cells , 2001, Pflügers Archiv.
[5] M. Alonso,et al. Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers , 1997 .
[6] Christopher T. Rhodes,et al. The spray drying of pharmaceuticals , 1992 .
[7] V. Préat,et al. Comparison of particle sizing techniques in the case of inhalation dry powders. , 2001, Journal of pharmaceutical sciences.
[8] R. Langer,et al. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[9] J. Patton,et al. (D) Routes of delivery: Case studies , 1992 .
[10] D. Walters. Lung Lining Liquid – The Hidden Depths , 2002, Neonatology.
[11] M. Alonso,et al. Investigation of a pMDI system containing chitosan microspheres and P134a , 1998 .
[12] D A Weitz,et al. Trojan particles: Large porous carriers of nanoparticles for drug delivery , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] G. Buckton,et al. The use of thermal techniques to assess the impact of feed concentration on the amorphous content and polymorphic forms present in spray dried lactose , 1997 .
[14] G. Buckton,et al. The effect of co-spray drying with polyethylene glycol 4000 on the crystallinity and physical form of lactose. , 2001, International journal of pharmaceutics.
[15] H. M. Nielsen,et al. The Potential of Chitosan in Enhancing Peptide and Protein Absorption Across the TR146 Cell Culture Model—An in Vitro Model of the Buccal Epithelium , 2002, Pharmaceutical Research.
[16] T. Boat,et al. Human lung lysozyme: sources and properties. , 1981, The American review of respiratory disease.
[17] S. Schürch,et al. Airway surfactant, a primary defense barrier: mechanical and immunological aspects. , 1996, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[18] M. Khan,et al. Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[19] O. Mertins,et al. Spray-dried indomethacin-loaded polyester nanocapsules and nanospheres: development, stability evaluation and nanostructure models. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[20] Lisbeth Illum,et al. Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2) , 1994, Pharmaceutical Research.
[21] T. Vandamme,et al. Pulmonary drug delivery systems: recent developments and prospects. , 2002, Critical reviews in therapeutic drug carrier systems.
[22] M. Alonso,et al. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. , 2001, International journal of pharmaceutics.
[23] J. Ward,et al. Control of pH of airway surface liquid of the ferret trachea in vitro. , 1990, Journal of applied physiology.
[24] S. Schürch,et al. Surfactant displaces particles toward the epithelium in airways and alveoli. , 1990, Respiration physiology.
[25] V. Préat,et al. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[26] Claus-Michael Lehr,et al. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers , 1992 .
[27] S. Akhtar,et al. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres , 1997 .
[28] Y. Kawashima,et al. A New Powder Design Method to Improve Inhalation Efficiency of Pranlukast Hydrate Dry Powder Aerosols by Surface Modification with Hydroxypropylmethylcellulose Phthalate Nanospheres , 1998, Pharmaceutical Research.
[29] Gerrit Borchard,et al. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro , 1996 .
[30] R. Müller,et al. In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. I. Effect of analytical parameters, particle size and particle concentration , 1992 .
[31] M. Alonso,et al. Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches. , 1997, Biomaterials.
[32] Kmg Taylor. Pulmonary drug delivery , 2002 .
[33] C. Remuñán-López,et al. Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles , 1999, Pharmaceutical Research.
[34] W. Finlay,et al. Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates. , 2000, International journal of pharmaceutics.
[35] Yu Zhang,et al. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. , 2004, International journal of pharmaceutics.
[36] L. Heinemann,et al. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. , 2000, Diabetes care.
[37] H. Ohshima,et al. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres , 2003 .
[38] J. Heyder,et al. Deposition of particles in the human respiratory tract in the size range 0.005–15 μm , 1986 .
[39] W. Finlay,et al. Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols , 1997 .
[40] George A. F. Roberts,et al. Advances in chitin science , 1997 .
[41] R. Muzzarelli,et al. Human enzymatic activities related to the therapeutic administration of chitin derivatives , 1997, Cellular and Molecular Life Sciences CMLS.